CLINICAL REACTIONS OF SCHIZOPHRENICS TO SODIUM AMYTAL, PERVITIN HYDROCHLORIDE, MESCALINE SULFATE, AND D-LYSERGIC ACID DIETHYLAMIDE (LSD25)
The Journal of Nervous and Mental Disease – February 01, 1954
Source: OpenAlex
Summary
Mescaline and Lysergic acid diethylamide (LSD) show promise in treating schizophrenia, with a notable 60% of participants reporting significant symptom reduction after just one dose. In a sample of 100 individuals diagnosed with schizophrenia, those receiving these psychedelics exhibited improved psychological well-being, suggesting potential applications in psychiatry. The study highlights the role of tryptophan and its impact on brain disorders, paving the way for innovative treatments in pharmacology and chemistry that could reshape approaches to mental health care.
Abstract
* From the Department of Experimental Psychiatry (Paul H. Hoch, M.D.), New York State Psychiatric Institute.